BX Swiss TOP 30 CHF
1.185,32
PKT
-2,74
PKT
-0,23
%
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 02.02.23 | ABB (Asea Brown Boveri) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.02.23 | Roche Hold | Jefferies & Company Inc. | |
| 02.02.23 | Novartis Underperform | Credit Suisse Group | |
| 02.02.23 | Novartis Sell | Deutsche Bank AG | |
| 02.02.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.23 | ABB (Asea Brown Boveri) Buy | Goldman Sachs Group Inc. | |
| 02.02.23 | ABB (Asea Brown Boveri) Outperform | RBC Capital Markets | |
| 02.02.23 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 02.02.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 02.02.23 | UBS Buy | Jefferies & Company Inc. | |
| 01.02.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.02.23 | Novartis Buy | Jefferies & Company Inc. | |
| 01.02.23 | Novartis Neutral | UBS AG | |
| 01.02.23 | UBS Neutral | Credit Suisse Group | |
| 01.02.23 | UBS Outperform | RBC Capital Markets | |
| 01.02.23 | UBS Buy | Goldman Sachs Group Inc. | |
| 01.02.23 | UBS Underweight | Barclays Capital | |
| 01.02.23 | UBS Buy | Deutsche Bank AG | |
| 01.02.23 | UBS Overweight | JP Morgan Chase & Co. | |
| 31.01.23 | UBS Buy | Goldman Sachs Group Inc. | |
| 31.01.23 | Givaudan Sell | UBS AG | |
| 31.01.23 | UBS Overweight | JP Morgan Chase & Co. | |
| 31.01.23 | UBS Buy | Jefferies & Company Inc. | |
| 31.01.23 | UBS Outperform | RBC Capital Markets | |
| 30.01.23 | Givaudan Underweight | Barclays Capital | |
| 30.01.23 | Roche Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 26.01.23 | Givaudan Add | Baader Bank | |
| 26.01.23 | Givaudan Hold | Deutsche Bank AG | |
| 25.01.23 | Givaudan Underweight | JP Morgan Chase & Co. | |
| 25.01.23 | Givaudan Underperform | Jefferies & Company Inc. | |
| 25.01.23 | Givaudan Sell | UBS AG | |
| 25.01.23 | Givaudan Add | Baader Bank | |
| 25.01.23 | Givaudan Underperform | Bernstein Research | |
| 25.01.23 | Roche Overweight | Barclays Capital | |
| 25.01.23 | Novartis Underweight | Barclays Capital | |
| 24.01.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.01.23 | UBS Buy | Goldman Sachs Group Inc. | |
| 23.01.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 20.01.23 | ABB (Asea Brown Boveri) Outperform | RBC Capital Markets | |
| 20.01.23 | Givaudan Underweight | Barclays Capital |